Evidence map›Paper›PMID 28920154›Full record

ArticleEuropean journal of clinical pharmacology2017

Pharmacokinetics of doripenem in plasma and epithelial lining fluid (ELF): comparison of two dosage regimens.

Zoe Oesterreicher, Iris Minichmayr, Robert Sauermann, Daniela Marhofer, Edith Lackner, Walter Jäger, Alexandra Maier-Salamon, Richard Schwameis, Charlotte Kloft, Markus Zeitlinger

Open access · hybridAbstract readComparative Study
In one paragraph

Article in European journal of clinical pharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. CarbapenemsHeliyon · 2023
    Article
  5. Review
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Zoe OesterreicherDepartment of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria.
Iris MinichmayrDepartment of Clinical Pharmacy and Biochemistry, Institute of Pharmacy, Freie Universitaet Berlin, Berlin, Germany.
Robert SauermannDepartment of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria.
Daniela MarhoferDepartment of Anaesthesia and Intensive Care Medicine, Medical University of Vienna, Vienna, Austria.
Edith LacknerDepartment of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria.
Walter JägerDepartment of Clinical Pharmacy and Diagnostics, University of Vienna, Vienna, Austria.
Alexandra Maier-SalamonDepartment of Clinical Pharmacy and Diagnostics, University of Vienna, Vienna, Austria.
Richard SchwameisDepartment of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria.
Charlotte KloftDepartment of Clinical Pharmacy and Biochemistry, Institute of Pharmacy, Freie Universitaet Berlin, Berlin, Germany.
Markus ZeitlingerDepartment of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria. markus.zeitlinger@meduniwien.ac.at.
Medical University of Vienna · ATFreie Universität Berlin · DEUniversity of Vienna · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeIn 2014, FDA released a warning for prescription of doripenem for ventilator-associated bacterial pneumonia due to unsatisfactory clinical cure rates. The present study explores if the observed lack of efficacy might be explained by insufficient target site pharmacokinetics in intensive care patients after two different infusion schemes.

methodsPlasma and bronchoalveolar lavage sampling was performed in 16 intubated patients with pneumonia receiving doripenem either as 1-h or as 4-h infusion. Doripenem concentrations were measured at steady state in plasma over 8 h, bronchoalvoelar lavage was performed in each patient once either after 0 h, 2 h, 4 h or 6 h.

resultsIn plasma, mean values of C

conclusionThe difference in plasma pharmacokinetics after 1-h and 4-h infusion reflects in the concentration versus time profile in the lung, but concentration at the target site was not only considerably lower but also subject to high inter-individual variability. We hypothesise that insufficient concentrations at the target site might have contributed to the previously described lack of clinical efficacy and confirmed the demand for assessment of target site pharmacokinetics in larger patient collectives.

Indexed as

AdultAgedAnti-Bacterial AgentsBody FluidsBronchoalveolar Lavage FluidCarbapenemsDoripenemDose-Response Relationship, DrugFemaleHumansMaleMiddle AgedPneumonia, Ventilator-AssociatedAnti-Bacterial AgentsCarbapenemsDoripenemDoripenemEpithelial lining fluidIntensive carePharmacokineticsPneumonia

Identifiers

PMID28920154
PMCPMC5684299
OpenAlexW2756044525

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.